AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction

MLA

Daniel Richards, et al. “AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.” Molecular Therapy: Methods & Clinical Development, vol. 18, Sept. 2020, pp. 607–19. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dcfeb821b6fd702f6a044ddc55770e72&authtype=sso&custid=ns315887.

APA

Daniel Richards, Thomas Wechsler, Khaled Hettini, Lillian Falese, Lin Gan, Michael C. Holmes, Robert J. Desnick, Annemarie Ledeboer, Makiko Yasuda, Kathleen Meyer, Silvere Pagant, Liching Cao, Stephen Ballaron, Yanmei Lu, Scott Sproul, Marshall W. Huston, & Susan St Martin. (2020). AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Molecular Therapy: Methods & Clinical Development, 18, 607–619.

Chicago

Daniel Richards, Thomas Wechsler, Khaled Hettini, Lillian Falese, Lin Gan, Michael C. Holmes, Robert J. Desnick, et al. 2020. “AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.” Molecular Therapy: Methods & Clinical Development 18 (September): 607–19. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....dcfeb821b6fd702f6a044ddc55770e72&authtype=sso&custid=ns315887.